Get the Stockscreener App
2.01
1.95%
-0.04
Bioline Rx Ltd Adr stock is traded at $2.01, with a volume of 12,580.
It is down -1.95% in the last 24 hours and down -18.95% over the past month.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
See More
Previous Close:
$2.05
Open:
$2.3
24h Volume:
12,580
Relative Volume:
0.63
Market Cap:
$10.01M
Revenue:
$1.41M
Net Income/Loss:
$-9.84M
P/E Ratio:
-0.9389
EPS:
-2.1408
Net Cash Flow:
$-7.85M
1W Performance:
-9.30%
1M Performance:
-18.95%
6M Performance:
-15.90%
1Y Performance:
-47.38%
1-Day Range:
$1.985
$2.30
1-Week Range:
$1.945
$2.3443
52-Week Range:
$1.945
$4.068
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Compare BLRX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
2.01 | 10.01M | 1.41M | -9.84M | -7.85M | -2.1408 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-17 | Upgrade | Maxim Group | Hold → Buy |
| Feb-13-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-12-16 | Downgrade | Maxim Group | Buy → Hold |
| Aug-17-15 | Reiterated | Maxim Group | Buy |
| Jul-27-15 | Reiterated | ROTH Capital | Buy |
| Jun-22-15 | Initiated | JMP Securities | Mkt Outperform |
View All
Bioline Rx Ltd Adr Stock (BLRX) Latest News
BioLineRx and Hemispherian to present GLIX1 data at SNO meeting - Investing.com
One covers lab models; another outlines a trial testing an experimental brain tumor treatment. - Stock Titan
BioLineRx Ltd. SEC Filing (Oct 5, 2026) - Stock Titan
Biolinerx Stock Price Forecast. Should You Buy BLRX? - StockInvest.us
BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates - kalkine.ca
Current ratio of BioLineRX Ltd. Sponsored ADR – HAN:YP2 - TradingView
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - lelezard.com
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
BioLineRx Files Form F-1 to Register Resale of 2,023,382 ADSs Linked to August 2026 Warrants - Kalkine Media
$5.6 million could go to BioLineRx (Nasdaq: BLRX) if all warrants are exercised for cash. - Stock Titan
Every proposal passed at BioLineRx (BLRX)’s September 23 annual meeting. - Stock Titan
BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates - Kalkine
BioLineRx Ltd.American Depositary Shares (Nasdaq:BLRX) Detailed Stock Data - The Chronicle-Journal
Diluted net income available to common stockholders of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView
Total revenue of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com
BioLineRx, Hemispherian to present GLIX1 data at EANO meeting - Investing.com
BioLineRx and Hemispherian to Showcase GLIX1 Glioblastoma Data and Trial Design at EANO 2026 - TipRanks
A drug candidate cut tumor growth and extended survival in mice. Human testing is enrolling. - Stock Titan
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) – Company AnnouncementFT.com - Financial Times
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - Yahoo Finance
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - PR Newswire
Long term debt to total assets ratio of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com
Return on equity % of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView
BioLineRx (BLRX) sells warrants to fund R&D push - Stock Titan
BioLineRX Ltd. Sponsored ADR Statistics – HAM:YP2 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
BLRX: New GLIX1 Data Touts Synergies - Yahoo Finance
BioLineRx Earnings Call Highlights GLIX1 Momentum - TipRanks
BioLineRx (NASDAQ: BLRX) Announces $3.3M Net Raise via 480,696 ADSs at $2.78 Each - Kalkine Media
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal - TipRanks
BioLineRx Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances - Investing.com
BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results - TipRanks
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
BioLineRx (BLRX) lines up new ADS and warrant funding round - Stock Titan
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ... - Yahoo Finance
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
BioLine RX Ltd (BLRX) JUN/2026 Earning Prediction - Intellectia AI
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Sahm
BioLineRx stock falls on $3.75M share offering plan - Investing.com India
BioLineRx stock falls on $3.75M share offering plan - Investing.com
BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility - TipRanks
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Barchart.com
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire
BioLineRx (BLRX) lines up $3.75M raise, ends ATM facility - Stock Titan
BioLineRx raises $3.75 million in registered direct offering - Investing.com
Bioline Rx Ltd Adr Stock (BLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):